Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers
- 6 November 2025
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (12) , 2399-2409
Abstract
Triple-negative breast cancer (TNBC) is best characterized by high aggressiveness and significant biological heterogeneity. Although the current TNBC clinical trials include genomic biomarkers to stratify treatment arms, they are still limited by metabolic heterogeneity within TNBC subtypes. The metabolic reprogramming, a cancer hallmark, in TNBC involves adaptive regulation of glycolysis, lipid metabolism, and oxidative phosphorylation (OXPHOS), with distinct metabolic phenotypes significantly influencing tumor sensitivity to treatment. Mitochondrial heterogeneity exacerbates the metabolic diversity of TNBC, with its dynamic functional regulation closely linked to cellular energy metabolism and signaling pathway adaptation. Interplay between OXPHOS, metabolites, and immune activity creates a self-reinforcing mechanism where metabolic adaptations in TNBC cells not only support their energy demands but also actively construct an immune-privileged niche that shields tumors from immune surveillance and limits the efficacy of treatments. These mechanisms and mitochondrial diversity could be heterogeneous and specific to TNBC subtypes. Thus, metabolic phenotyping of TNBC subtypes could reveal previously unidentified patient subgroups, potentially explaining divergent survival outcomes and offering metabolism-targeted therapeutic strategies that might improve outcomes for patients who currently lack effective treatment alternatives.Keywords
This publication has 78 references indexed in Scilit:
- MYC/TET3‐Regulated TMEM65 Activates OXPHOS‐SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple‐Negative Breast CancerAdvanced Science, 2025
- Targeting LAT1 with JPH203 to reduce TNBC proliferation and reshape suppressive immune microenvironment by blocking essential amino acid uptakeAmino Acids, 2025
- Adjuvant Atezolizumab for Early Triple-Negative Breast CancerJAMA, 2025
- Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancerCancer Medicine, 2024
- 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II studyAnnals of Oncology, 2023
- TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2‐mediated glycolysisCancer Medicine, 2023
- Potential role of mitochondria-associated endoplasmic reticulum membrane proteins in diseasesBiochemical Pharmacology, 2022
- Loss of GLUT4 Induces Metabolic Reprogramming and Impairs Viability of Breast Cancer CellsJournal of Cellular Physiology, 2014
- A fatty acid‐binding protein 7/RXRβ pathway enhances survival and proliferation in triple‐negative breast cancerThe Journal of Pathology, 2012
- Association of FABP5 Expression With Poor Survival in Triple-Negative Breast CancerThe American Journal of Pathology, 2011